Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of dapagliflozin + metformin versus XIGDUO XR in healthy Thai adults under fasting conditions
TCTR20260913003Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + metformin, dapagliflozin and metformin (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration (Cmax), Area under the plasma concentration-time curve to last measurable concentration (AUC0-t) and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dapagliflozin + metformindapagliflozinmetformin
Beyond the preview
Go deeper on TCTR20260913003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260913003.